Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 17, 2018. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions occurred on July 12, 2018, on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).
Key Financial Metrics
The filing does not contain company-wide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Instrument | Transaction Type | Price | Total Volume |
|---|---|---|---|
| Ordinary Shares (GBP) | Acquisition via Dividend Re-investment | £15.766 | 4,671 shares |
| American Depositary Shares (USD) | Acquisition via Dividend Re-investment | $41.75 | 660 ADSs |
Note: Total volumes are aggregated from individual PDMR transactions listed in the filing.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It reports routine acquisitions of company stock by executives as part of the Deferred Annual Bonus Plan following the dividend payment on July 12, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions are administrative in nature, resulting from the automatic re-investment of dividends.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares or ADSs via dividend re-investment, not open market purchases or sales.
- Participants: Transactions involved 12 senior executives, including the CEO (Ms. E. Walmsley), CFO (Mr. S. Dingemans), and various Presidents and SVPs.
- Valuation: The share price at the time of transaction was £15.766 for Ordinary Shares and $41.75 for ADSs.
- Scope: This filing is a regulatory disclosure of insider holdings changes and does not reflect the company's broader financial health or operational results.